FMC (FMC) faces several risks to its 2025 outlook such as increasing leverage, limited free cash flow, and ongoing headwinds for its diamide products, BofA Securities said in a Wednesday note.
The company reported its Q4 results late Tuesday, with higher adjusted earnings and revenue, and issued its outlook for Q1 and 2025. According to BofA Securities, FMC's Q1 guidance was "very soft" and 2025 targets were "weak" overall.
"FMC's diamide updates included a worse-than-expected outlook," the investment firm said, noting that the business' generic competition continued to expand.
BofA Securities said the company also faces the risk of downgrade to a non-investment grade credit rating and growth initiatives could take longer than expected to deliver benefits.
BofA Securities downgraded FMC to underperform from neutral and lowered its price target to $48 from $61.
Shares of FMC were down more than 33% in recent Wednesday trading.
Price: 35.85, Change: -18.19, Percent Change: -33.66
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。